R&D Trends

Takeda, Altos Therapeutics partner for the treatment of gastroparesis

Tuesday, July 5, 2016

Takeda Pharmaceutical and Altos Therapeutics have entered into a definitive agreement to further the development of Altos’ proprietary compound ATC-1906. Additionally, the agreement includes an exclusive option for Takeda to acquire Altos beginning on the date of the agreement and continuing for a period of time following the completion of ongoing phase I studies of ATC-1906. The parties envision future development of ATC-1906 for the treatment of gastroparesis (GP) and its symptoms.

[Read More]

Four NCI Cancer Centers form Consortium, collaborate with Celgene

Tuesday, June 28, 2016

The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai announced the establishment of a research consortium focused on accelerating the discovery and development of novel cancer therapeutics and diagnostics for the benefit of patients.

[Read More]

Takeda, M2Gen to generate broad genomic data from consenting cancer patients

Monday, June 20, 2016

Takeda Pharmaceutical and M2Gen, a healthcare informatics solutions company, have established a new collaboration to generate broad genomic data from consenting cancer patients. Under the agreement, Takeda will help build the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program based on the Total Cancer Care Protocol, a prospective observational study enrolling patients with various cancers, and access information generated under this program.

[Read More]

Cell Medica, Baylor partner on cancer treatments

Monday, June 20, 2016

Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and infections, has announced a co-development partnership with Baylor College of Medicine to develop next-generation technologies for engineering immune cells with enhanced functions for the treatment of solid tumors. The collaboration provides Cell Medica with an exclusive license over several Baylor cell and gene technologies and an option to license new products introduced into the co-development partnership by Baylor’s leading research teams in the field of genetically engineered immune cells.

[Read More]